Pharmaceutical

MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

Oct 20, 2024 - 04:00
MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win
A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.
Read the original article

Tags:

Previous Article

Intercept’s liver disease drug Ocaliva faces FDA approval delay

Next Article

Avadel wins FDA approval for narcolepsy drug Lumryz in children

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bladder cancer diagnoses to top 300,000 in major markets by 2033

Bladder cancer diagnoses to top 300,000 in major market...

Nov 1, 2024

Self-amplifying RNA and vaccine innovation: getting from concept to clinic

Self-amplifying RNA and vaccine innovation: getting fro...

May 29, 2024

STAT+: Do GLP-1s have a future treating alcoholism?

STAT+: Do GLP-1s have a future treating alcoholism?

Dec 3, 2023